Skip to content

Stabilizing Psilocybin Pharmacology and Tuning Safety with Atypical Antipsychotic Cotherapy

Anna C. Renner, Robert B. Kargbo

ACS Medicinal Chemistry Letters October 10, 2025 DOI: 10.1021/acsmedchemlett.5c00595 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Preclinical study Peer reviewed
Population Organoid and animal models
Interventions crystalline cocrystal of psilocin and psilocybin adjunctive atypical antipsychotics
Topics Psilocybin
Key points A crystalline cocrystal of psilocin and psilocybin enhances exposure, neuroplasticity biomarkers, and functional activity, while adjunctive atypical antipsychotics modulate serotonergic signaling to mitigate 5-HT2B-linked safety concerns.

Abstract

A crystalline cocrystal of psilocin and psilocybin enhances exposure, neuroplasticity biomarkers, and functional activity, while adjunctive atypical antipsychotics modulate serotonergic signaling to mitigate 5-HT2B-linked safety concerns. Together, these inventions advance formulation, mechanistic selectivity, and translational biomarkersoffering a chemistry-enabled path to scalable psychedelic therapy with improved cardiac safety and durable neuroplastic responses across organoid and animal models.

Comparable studies

Other preclinical and animal studies on psilocybin, most cited first.

Citations in the library

Explore topics